The effects of CV205-502 in patients with hyperprolactinaemia intolerant and/or resistant to bromocriptine.

2.50
Hdl Handle:
http://hdl.handle.net/10541/99778
Title:
The effects of CV205-502 in patients with hyperprolactinaemia intolerant and/or resistant to bromocriptine.
Authors:
Razzaq, R; O'Halloran, Domhnall J; Beardwell, Colin G; Shalet, Stephen M
Abstract:
CV205-502 is a new non-ergot dopamine agonist currently being studied for the treatment of hyperprolactinaemia. We have assessed the effects of CV205-502 on prolactin secretion and the clinical consequences of hyperprolactinaemia in 16 patients with hyperprolactinaemia who had previously been unsuccessfully treated with bromocriptine. These patients had been either intolerant of and/or resistant to the effects of bromocriptine. Sixteen patients, all women in an age range between 20 and 49 years (mean 31.5 years), were treated for periods of between 8 and 52 weeks with doses of CV205-502 ranging from 0.075 to 0.3 mg taken once daily at night. Seven out of 10 of the patients, who were intolerant of bromocriptine, tolerated CV205-502 better with fewer side effects although the nature of the side effects was similar to that associated with bromocriptine. Only 1 patient from this group stopped taking CV205-502 due to side effects. Six of 11 patients exhibiting bromocriptine resistance showed a significant reduction in the degree of hyperprolactinaemia but normoprolactinaemia was achieved in only 1. Galactorrhoea ceased in 2 of 6 patients, menstruation resumed in 6 of 11 patients presenting with amenorrhoea, and 2 patients conceived. In patients with bromocriptine intolerance and/or resistance, CV205-502 is useful as a second line treatment.
Affiliation:
Department of Clinical Endocrinology, Christie Hospital, Manchester, UK.
Citation:
The effects of CV205-502 in patients with hyperprolactinaemia intolerant and/or resistant to bromocriptine. 1993, 39 (5-6):218-22 Horm. Res.
Journal:
Hormone Research
Issue Date:
1993
URI:
http://hdl.handle.net/10541/99778
DOI:
10.1159/000182739
PubMed ID:
7906243
Type:
Article
Language:
en
ISSN:
0301-0163
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorRazzaq, Ren
dc.contributor.authorO'Halloran, Domhnall Jen
dc.contributor.authorBeardwell, Colin Gen
dc.contributor.authorShalet, Stephen Men
dc.date.accessioned2010-05-25T11:47:25Z-
dc.date.available2010-05-25T11:47:25Z-
dc.date.issued1993-
dc.identifier.citationThe effects of CV205-502 in patients with hyperprolactinaemia intolerant and/or resistant to bromocriptine. 1993, 39 (5-6):218-22 Horm. Res.en
dc.identifier.issn0301-0163-
dc.identifier.pmid7906243-
dc.identifier.doi10.1159/000182739-
dc.identifier.urihttp://hdl.handle.net/10541/99778-
dc.description.abstractCV205-502 is a new non-ergot dopamine agonist currently being studied for the treatment of hyperprolactinaemia. We have assessed the effects of CV205-502 on prolactin secretion and the clinical consequences of hyperprolactinaemia in 16 patients with hyperprolactinaemia who had previously been unsuccessfully treated with bromocriptine. These patients had been either intolerant of and/or resistant to the effects of bromocriptine. Sixteen patients, all women in an age range between 20 and 49 years (mean 31.5 years), were treated for periods of between 8 and 52 weeks with doses of CV205-502 ranging from 0.075 to 0.3 mg taken once daily at night. Seven out of 10 of the patients, who were intolerant of bromocriptine, tolerated CV205-502 better with fewer side effects although the nature of the side effects was similar to that associated with bromocriptine. Only 1 patient from this group stopped taking CV205-502 due to side effects. Six of 11 patients exhibiting bromocriptine resistance showed a significant reduction in the degree of hyperprolactinaemia but normoprolactinaemia was achieved in only 1. Galactorrhoea ceased in 2 of 6 patients, menstruation resumed in 6 of 11 patients presenting with amenorrhoea, and 2 patients conceived. In patients with bromocriptine intolerance and/or resistance, CV205-502 is useful as a second line treatment.en
dc.language.isoenen
dc.subject.meshAdult-
dc.subject.meshAmenorrhea-
dc.subject.meshAminoquinolines-
dc.subject.meshBromocriptine-
dc.subject.meshDopamine Agents-
dc.subject.meshDrug Resistance-
dc.subject.meshDrug Tolerance-
dc.subject.meshFemale-
dc.subject.meshGalactorrhea-
dc.subject.meshHumans-
dc.subject.meshHyperprolactinemia-
dc.subject.meshMiddle Aged-
dc.subject.meshPregnancy-
dc.subject.meshProlactin-
dc.titleThe effects of CV205-502 in patients with hyperprolactinaemia intolerant and/or resistant to bromocriptine.en
dc.typeArticleen
dc.contributor.departmentDepartment of Clinical Endocrinology, Christie Hospital, Manchester, UK.en
dc.identifier.journalHormone Researchen
All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.